The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Acquired chemotherapy resistance in ovarian cancer
Open accessAbstract
Most women diagnosed with high-grade serous ovarian cancer (HGSC) develop recurrent disease and chemotherapy resistance, despite initially responding to treatment. The genomic characteristics of HGSC samples collected at initial surgery have been extensively studied. However, due to challenges of sample collection following treatment, much less is known about the molecular features of recurrent disease. Our recent studies have identified mechanisms of acquired resistance and biomarkers in recurrent HGSCs that could lead to improved treatment approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the majority of OvCa patients that initially respond to chemotherapy treatment develop the recurrent disease due to acquired resistance to platinum-based chemotherapy after undergoing multiple cycles of chemotherapy36.”
From Large-scale integrated analysis of ovarian cancer tumors and cell lines identifies an individualized gene expression signature for predicting response to platinum-based chemotherapy (2019) · cites this paper as [36]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“High-grade serous ovarian cancers (HGSOC) are the most prevalent type of epithelial ovarian tumors (about 75%) and characterized by TP53 driver mutations and extensive genome rearrangement (Christie and Bowtell, 2017).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Christie and Bowtell, 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Whole–genome characterization of chemoresistant ovarian cancer
Patch, A., Christie, E. L., Etemadmoghadam, D., Garsed, D. W., George, J., Fereday, S., Nones, K., Cowin, P. A., Alsop, K., Bailey, P. J., et al. (2015) · Nature · doi:10.1038/nature14410 · Cited by 1,572
Self-citationRethinking ovarian cancer: recommendations for improving outcomes
Vaughan, S., Coward, J. I. G., Bast, R. C., Berchuck, A., Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. P., Drapkin, R., Etemadmoghadam, D., et al. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3144 · Cited by 1,484
Self-citationAlsop, K., Fereday, S., Meldrum, C. J., DeFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M. J., Webb, P. M., Stewart, C. J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8545 · Cited by 1,204
Self-citationDriver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
Ahmed, A. A., Etemadmoghadam, D., Temple, J., Lynch, A. G., Riad, M., Sharma, R. N., Stewart, C. J. R., Fereday, S., Caldas, C., DeFazio, A., et al. (2010) · The Journal of Pathology · doi:10.1002/path.2696 · Cited by 815
Self-citationNorquist, B. M., Wurz, K., Pennil, C. C., Garcia, R. L., Gross, J., Sakai, W., Karlan, B. Y., Taniguchi, T., & Swisher, E. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.2980 · Cited by 593
Evolution of platinum resistance in high-grade serous ovarian cancer
Cooke, S. L., & Brenton, J. D. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70123-1 · Cited by 213
Christie, E. L., Fereday, S., Doig, K., Pattnaik, S., Dawson, S., & Bowtell, D. D. L. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.4627 · Cited by 198
Self-citationDNA-PK Mediates AKT Activation and Apoptosis Inhibition in Clinically Acquired Platinum Resistance
Stronach, E. A., Chen, M. M., Maginn, E. N., Agarwal, R., Mills, G. B., Wasan, H. S., & Gabra, H. (2011) · Neoplasia · doi:10.1593/neo.111032 · Cited by 138
Cited by
Sorted by citations
Items 101–200 of 221
Li, G., Gong, J., Cao, S., Wu, Z., Cheng, D., Zhu, J. X., Huang, X., Tang, J., Yuan, Y., Cai, W.-Q., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.742149 · Cited by 10
Lanthanum Chloride Sensitizes Cisplatin Resistance of Ovarian Cancer Cells via PI3K/Akt Pathway
Fang, S., Zhang, P., Chen, X., Liu, F., & Wang, F. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.776876 · Cited by 10
Hassan, B. A. R., Mohammed, A. H., Alsammarraie, A. Z., Alabboodi, M. K., Wayyes, A. M., Ahmed, A. A., & Shanshal, A. M. (2022) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2022.23.12.4275 · Cited by 10
Synergistic effect of PARP inhibitor and BRD4 inhibitor in multiple models of ovarian cancer
Huang, Y., Liu, C., Li, X., Hu, D., Xiao, R., Qin, X., Guo, E., Yang, B., Li, X., Fan, J., et al. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17683 · Cited by 10
Mao, M., Zheng, X., Sheng, Y., Chai, J., & Ding, H. (2023) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14228 · Cited by 10
Pain nursing for gynecologic cancer patients
Wu, W., He, X., Li, S., Jin, M. L., & Ni, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1205553 · Cited by 13
Radix ranunculus temate saponins sensitizes ovarian cancer to Taxol via upregulation of miR‑let‑7b
You, K., Liu, Y., Chen, L., Ye, H., & Lin, W. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11244 · Cited by 9
Wang, J., Li, H., Wang, L., Zhang, J., Li, M., Qiao, L., Zhang, J., Liu, L., Zhang, C., Gao, J., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.681250 · Cited by 9
Revealing the inhibitory effect of VASH1 on ovarian cancer from multiple perspectives
Li, Y., Meng, L., & Lou, G. (2023) · Cancer Biology & Therapy · doi:10.1080/15384047.2023.2285817 · Cited by 9
Kou, X., Ding, H., Li, L., & Chao, H. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-4321 · Cited by 10
Singh, N. J., Hutson, R., Milton, N. G. N., & Javid, F. A. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174752 · Cited by 9
Zhao, H., Bi, F., Li, M., Diao, Y., & Zhang, C. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.110961 · Cited by 9
Khedkar, N. R., Sindkhedkar, M. D., & Joseph, A. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.107027 · Cited by 9
Exploring the Clinical Impact of Predictive Biomarkers in Serous Ovarian Carcinomas
Page, C. L., Chung, J. W., Rahimi, K., Köbel, M., Provencher, D. M., & Mes‐Masson, A. (2019) · Current Drug Targets · doi:10.2174/1389450120666191016143836 · Cited by 9
Hassan, R. A., Mahmoud, Z., Elmaaty, A. A., Elnagar, M. R., Abdou, A. M., El-Haleem, A. H. A., & Hamed, M. I. A. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108921 · Cited by 8
The hidden hand of endoplasmic reticulum stress in anticancer drug resistance
Khan, J. T., Sood, S., Piedra, V., Seker, E., Rajak, H., Karthikeyan, C., Ashby, C. R., Pathak, R., & Tiwari, A. K. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104998 · Cited by 8
Zhu, J., Hu, Y. B., Yang, C., Li, F., Yang, B., Li, R., Qiu, B., Li, Y., & Liu, L. (2024) · ACS Applied Nano Materials · doi:10.1021/acsanm.3c05036 · Cited by 8
Impact of Obesity and Lysosomal Dysfunction on Chemoresistance in Ovarian Cancer
Kim, B., & Jung, J. (2024) · Biomedicines · doi:10.3390/biomedicines12030604 · Cited by 8
Li, J., Chen, M., Huang, D., Li, Z., Chen, Y., Huang, J., Chen, Y. Y., Zhou, Z., & Yu, Z. (2024) · MedComm · doi:10.1002/mco2.70033 · Cited by 7
Meyer-Wilmes, P., Kennes, L. N., Ignatov, A., Goetz, F., Wittenborn, J., Stickeler, E., & Tchaikovski, S. N. (2025) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-025-08095-3 · Cited by 7
Zitzmann-Kolbe, S., Kristian, A., Zopf, D., Kamfenkel, C., Politz, O., Ellingsen, C., Hilbig, J., Juul, M. U., Fonslet, J., Nielsen, C. H., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0808 · Cited by 7
Yang, B., Yang, J., & Zhang, K. (2024) · Discover Oncology · doi:10.1007/s12672-024-00981-7 · Cited by 7
Guo, R., Qia, X., Liu, L., Liu, H., Liu, Y., Wei, W., & Qin, Y. (2021) · Journal of Cancer · doi:10.7150/jca.62285 · Cited by 7
Li, M., Zhang, L., Feng, M., & Huang, X. (2022) · Journal of Immunology Research · doi:10.1155/2022/3258400 · Cited by 7
Role of exosomal noncoding RNA in esophageal carcinoma
Si, M.-Y., Rao, D., Xia, Y., Sang, C., Mao, K.-Y., Liu, X.-J., Zhang, Z., & Tang, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1126890 · Cited by 7
RUNX1-Regulated Signaling Pathways in Ovarian Cancer
Chen, Y., He, Y., & Liu, S. (2023) · Biomedicines · doi:10.3390/biomedicines11092357 · Cited by 7
Purified Vitexin Compound 1 Serves as a Promising Antineoplastic Agent in Ovarian Cancer
Ma, K., Wang, K., Zhou, Y., Liu, N., Guo, W. M., Qi, J., Zhen-min, H., Su, S., Tang, P. T. P., & Zhou, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.734708 · Cited by 7
Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer
Scotto, G., Borella, F., Turinetto, M., Tuninetti, V., Valsecchi, A. A., Giannone, G., Cosma, S. D., Benedetto, C., & Valabrega, G. (2021) · Cells · doi:10.3390/cells10123408 · Cited by 8
Role of Cancer Side Population Stem Cells in Ovarian Cancer Angiogenesis
Pan, Y., Yang, X., Chen, M., Shi, K., Lyu, Y., Meeson, A. P., & Lash, G. E. (2024) · Medical Principles and Practice · doi:10.1159/000539642 · Cited by 6
Zhu, Y., Chen, J., Zhou, L., Zhang, L., Liu, Y., Zhuang, Y.-X., Lin, P., & Huang, Y. (2022) · Journal of Oncology · doi:10.1155/2022/7625138 · Cited by 6
Liu, Q., Jiang, L., Zhao, Y., Su, F., Li, J., Tian, X., Liu, W., Jiang, X., Xu, Y., & Tao, F. (2024) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2024.5384 · Cited by 6
Wu, P., Chen, J., Li, H., Lu, H., Li, Y., & Zhang, J. (2024) · Oncology Reports · doi:10.3892/or.2024.8851 · Cited by 7
Li, M., Tian, Y., Si, L., Fu, H., Lai, T., & Guo, R. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2024.114011 · Cited by 6
Ricci, F., Corbelli, A., Affatato, R., Chilà, R., Chiappa, M., Brunelli, L., Fruscio, R., Pastorelli, R., Fiordaliso, F., & Damia, G. L. M. (2021) · PubMed Central · doi:10.5281/zenodo.5816703 · Cited by 6
Fan, L., Zheng, N., Peng, F., Zhao, Z., Fan, D., Cai, S., Tao, L., & Wang, Q. (2020) · Cancer Science · doi:10.1111/cas.14436 · Cited by 6
PAUF as a Target for Treatment of High PAUF-Expressing Ovarian Cancer
Kim, Y., Jiang, F., Park, J. H., Jeong, H. H., Baek, J. E., Hong, S., Jeong, S., & Koh, S. S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.890614 · Cited by 6
Onyido, E. K., James, D. H., García-Parra, J., Sinfield, J. K., Moberg, A., Coombes, Z., Worthington, J., Williams, N., Francis, L. W., Conlan, R. S., et al. (2023) · Antibodies · doi:10.3390/antib12040065 · Cited by 5
Abujamous, L., Soltani, A., Al-Thawadi, H., & Agouni, A. (2023) · Biomolecules and Biomedicine · doi:10.17305/bb.2023.9757 · Cited by 5
Alam, S., & Giri, P. K. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2023.152 · Cited by 5
Duraki, D., Jabeen, M., Mao, C., Wang, L., Ghosh, S., Dai, X., Zhu, J., Boudreau, M. W., Nelson, E. R., Hergenrother, P. J., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217738 · Cited by 5
Wang, W., Guo, H., Wu, S., Xian, S., Zhang, W., Zhang, R., Chen, Z., Su, K., Zhang, Y., Zhu, Y., et al. (2023) · Reproductive Sciences · doi:10.1007/s43032-022-01134-3 · Cited by 5
New insights into the role of circular RNAs in ovarian cancer
Xing, Y., Liang, X., Lv, X., Cheng, Y., Du, J., Liu, C., & Yang, Y. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.154073 · Cited by 4
Evolutionary mode and timing of dissemination of high-grade serous carcinomas
Sveen, A., Johannessen, B., Klokkerud, S. M. K., Kraggerud, S. M., Meza‐Zepeda, L. A., Bjørnslett, M., Bischof, K., Myklebost, O., Taskén, K., Skotheim, R. I., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.170423 · Cited by 4
Xiong, Z., Ha, C., Li, R., Wu, M., & Meng, W. (2024) · Gynecologic and Obstetric Investigation · doi:10.1159/000539295 · Cited by 4
Expressions and clinical significances of STAT3 and Grim19 in epithelial ovarian cancer
Wang, Y., Yan, Y., Yang, M., & Yang, Z. (2020) · 3 Biotech · doi:10.1007/s13205-020-02237-x · Cited by 4
Mechanisms of chemoresistance and approaches to overcome its impact in gynecologic cancers
Sabnis, N. A., Mathew, E., Dossou, A. S., Zheng, A., Nagarajan, B., Fudala, R., & Lacko, A. G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824299-5.00008-3 · Cited by 4
Zhou, Z., Li, J., Shen, J., Shi, W., Xu, Y., Ye, L., Liu, J., & Pan, J. (2022) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2022195 · Cited by 4
Elafin is related to immune infiltration and could predict the poor prognosis in ovarian cancer
Lu, W., Xie, B., Tan, G., Dai, W., Ren, J., Pervaz, S., Li, K., Li, F., Wang, Y., & Wang, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1088944 · Cited by 4
Wu, Y., Gao, Y., Chen, L., Jin, X., Chen, P., & Mo, Q. (2021) · Clinical & Experimental Immunology · doi:10.1111/cei.13639 · Cited by 4
Ren, L., Huo, X., & Zhao, Y. (2024) · iScience · doi:10.1016/j.isci.2024.110861 · Cited by 3
Lys-ing the Resistance: Targeting Lysosomes to Overcome Chemoresistance in Ovarian Cancer
Vayalapalli, A., Kacsoh, B. Z., & Chefetz, I. (2026) · Current Oncology Reports · doi:10.1007/s11912-026-01742-1 · Cited by 3
CLCN3 in mediating the proliferation of human ovarian cancer cells
Ren, L., Li, Y., Feng, Y., Zhang, Z., Yang, H., & Li, M. (2024) · Translational Cancer Research · doi:10.21037/tcr-23-1272 · Cited by 3
Yuan, G., Zhang, K., Zheng, H., Wu, Y., Sun, H., Zhang, J., Sun, X., & Wu, L. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.05.005 · Cited by 3
Fan, W., Zhang, Y., Yang, X., Liu, Z., Wu, X., Li, L., Zhao, T., Li, H., Liu, X., Cui, D., et al. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177698 · Cited by 3
Zeng, F., Liu, Y., Ouyang, Q., Sun, Z., Zhang, K., Li, X., & Liu, Y. (2021) · Journal of Chemotherapy · doi:10.1080/1120009x.2021.1913702 · Cited by 3
Non-Coding RNAs Delivery by Small Extracellular Vesicles and Their Applications in Ovarian Cancer
Liu, M., Zhou, X., & Tang, J. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.876151 · Cited by 3
Liu, X., Zhao, Y., Jiao, X., Yu, Y., Li, R., Zeng, S., Chi, J., Ma, G., Huo, Y., Li, M., et al. (2022) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.17329 · Cited by 3
Foster, K. I., Handley, K. F., Glassman, D., Sims, T. T., Javadi, S., Palmquist, S. M., Saleh, M. M., Fellman, B. M., Fleming, N. D., Bhosale, P., et al. (2023) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2022-004206 · Cited by 3
Ma, S., Zhou, L., Liu, Y., Jie, H., Yi, M., Guo, C., Mei, J., Li, C., Zhu, L., & Deng, S. (2025) · PLoS ONE · doi:10.1371/journal.pone.0322130 · Cited by 2
Wang, W., Alvero, A. B., Qin, Y., Wang, M., Fox, A. L., Li, Y., Millman, M., Kemper, A., Mor, G., Liu, X., et al. (2026) · Molecular Oncology · doi:10.1002/1878-0261.70224 · Cited by 2
Photoacoustic Imaging for Women’s Gynecological Health: Advances and Clinical Prospects
Kumar, P. P. P., Lim, D., & Kim, T. (2026) · Bioengineering · doi:10.3390/bioengineering13040476 · Cited by 2
Yan, Z., Jin, Z., Sui, H., Peng, K.-H., & Shi, C. (2022) · Revista Brasileira de Farmacognosia · doi:10.1007/s43450-022-00243-z · Cited by 2
Li, S., Zhang, J., Du, W., Ren, X., & Zhang, X. (2022) · Gland Surgery · doi:10.21037/gs-22-420 · Cited by 2
Li, L., Zhang, J., Li, H., Qin, L., Wu, H., Li, Z., Cai, L., Chen, D., Yang, J., Chen, Y., et al. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123663 · Cited by 2
Structural insights into the promutagenic bypass of the major cisplatin-induced DNA lesion
Ouzon‐Shubeita, H., Vilas, C. K., & Lee, S. (2020) · Biochemical Journal · doi:10.1042/bcj20190906 · Cited by 2
HOXC10 promotes carboplatin resistance of ovarian cancer by regulating ABCC3.
Li, Y., Han, L., Hai, R., Shu, G., Yan, W., & Yin, G. (2022) · PubMed Central · Cited by 2
Wu, C.-H., Feng, C., Wang, C., Wen, Z., Long, C., & Tang, F. (2023) · Cancers · doi:10.3390/cancers15051586 · Cited by 2
Rausio, H., Cervera, A., Heuser, V. D., West, G., Oikkonen, J., Pianfetti, E., Lovino, M., Ficarra, E., Taimen, P., Hynninen, J., et al. (2024) · Neoplasia · doi:10.1016/j.neo.2024.100987 · Cited by 2
Sartini, S., Omholt, L., Moatamed, N. A., & Soragni, A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.17.612958 · Cited by 2
Wang, L., He, M., Zhu, X., Ma, L., Zhong, L., Jiang, Q., Li, Q., Wu, H., Wang, H., & Zou, D. (2026) · Journal of Ovarian Research · doi:10.1186/s13048-026-02178-8 · Cited by 1
Vescio, M., Paracchini, L., Beltrame, L., D’Incalci, M., Marchini, S., & Pattini, L. (2023) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2023.100088 · Cited by 1
Zhang, Z., Chen, M., & Peng, X. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e33367 · Cited by 1
MicroRNA‐505‐3p mediates cell motility of epithelial ovarian cancer via suppressing PEAK1 expression
Wu, Y., Xue, L., Xiong, W., Li, H., Wu, J., Xie, W., Long, Y., Liu, Y., & Luo, C. (2024) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23767 · Cited by 1
Yang, L., Yu, H., Touna, A., Yin, X., Zhang, Q., & Leng, T. (2021) · Pharmacognosy Magazine · doi:10.4103/pm.pm_111_20 · Cited by 1
Pache, B. C.-E., Farinha, H. T., Toussaint, L., Demartines, N., Hastir, D., Mathevet, P., Sempoux, C. L., & Hübner, M. (2022) · Frontiers in Surgery · doi:10.3389/fsurg.2022.936613 · Cited by 1
RAC1/miR-3613/RAC1 feedback loop contributes to ovarian cancer progressionPreprint
Li, C., Leng, R., Meng, Y., Li, N., Li, F., & Zhao, Y. (2021) · Research Square · doi:10.21203/rs.3.rs-380396/v1 · Cited by 1
Yamanoi, K., Ogura, J., Nakamura, E., Ito, S., Nakanishi, Y., Menju, T., Kawaguchi, K., Hosoe, Y., Taki, M., Murakami, R., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3680771/v1 · Cited by 1
Overcoming drug resistance in ovarian cancer: Chemo-sensitizing agents, targeted therapies
Muppala, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824299-5.00015-0
Ghoneum, A., Tazzite, A., Bairi, K. E., & Said, N. A. (2021) · Springer eBooks · doi:10.1007/978-981-16-1873-4_7
Identification of SnoRNAs Predicting Prognosis for Ovarian CancerPreprint
Zhu, W., Zhang, T., Luan, S., Kong, Q., Hu, W., Zou, X., Zheng, F., & Han, W. (2021) · Research Square · doi:10.21203/rs.3.rs-1022969/v1
Synergistic Effect of PARP Inhibitor and BRD4 Inhibitor in Multiple Models of Ovarian CancerPreprint
Huang, H. Y., Liu, C., You, X. L., Li, X., Sun, Y., & Chen, G. (2021) · Research Square · doi:10.21203/rs.3.rs-1147194/v1
Toward understanding the roles of matrix metallopeptidase 1 in ovarian cancer
Cassie, H., Coogan, I., Hee, S. J., Yao Derek, Y., Olivia, N., Parmida, J., Berchuck, A., Murphy Susan, K., & Huang, Z. (2023) · Journal of Gynecological Research and Obstetrics · doi:10.17352/jgro.000120
Wu, J., Wu, Y., Guo, Q., Shao, Y. W., chen, S., Liu, C., Lin, K., Wang, S., Zhu, J., Chen, X., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2819489/v1
Feng, L., Huang, Y., Zhang, W., & Li, L. (2021) · Figshare · doi:10.6084/m9.figshare.14601888
Wang, X., Jiang, L., & Liu, Q. (2022) · TigerPrints (Clemson University) · doi:10.6084/m9.figshare.20025768
Wang, X., Jiang, L., & Liu, Q. (2022) · TigerPrints (Clemson University) · doi:10.6084/m9.figshare.20025771
Leung, J. H., Leung, H. W. C., Wang, S.-Y., Fion, H.-T. Y., & Chan, A. L. F. (2024) · Medicine · doi:10.1097/md.0000000000038183
New Treatments for Chemoresistant Ovarian Cancer: A Systematic Review
Gimenez‐Bonafé, P., & Dols, M. G. (2024) · Revisiones en cáncer · doi:10.20960/revcancer.00086
Du, N., Li, Y., Zheng, H., Liu, Y., Liu, L., Xie, J., & Kang, S. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1461772
Tumor-on-a-Chip: From Biomimetic Tumor-Immune Microenvironments to Therapeutic Insights
Çetin, Y. (2025) · Biochemistry · doi:10.5772/intechopen.1012047
Mesquita, F. A. S., Nakano, L. K. M., de Amorim, I. F. G., Salles, P. G. D. O., & Pereira, R. D. A. (2025) · Mário Penna Journal · doi:10.61229/mpj.v2i2.51
Additional file 9 of The R-enantiomer of ketorolac reduces ovarian cancer tumor burden in vivo
Grimes, M. M., Kenney, S. R., Dominguez, D. R., Brayer, K. J., Guo, Y., Wandinger‐Ness, A., & Hudson, L. G. (2021) · Figshare · doi:10.6084/m9.figshare.13545602
Additional file 1 of The R-enantiomer of ketorolac reduces ovarian cancer tumor burden in vivo
Grimes, M. M., Kenney, S. R., Dominguez, D. R., Brayer, K. J., Guo, Y., Wandinger‐Ness, A., & Hudson, L. G. (2021) · Figshare · doi:10.6084/m9.figshare.13545575
Additional file 7 of The R-enantiomer of ketorolac reduces ovarian cancer tumor burden in vivo
Grimes, M. M., Kenney, S. R., Dominguez, D. R., Brayer, K. J., Guo, Y., Wandinger‐Ness, A., & Hudson, L. G. (2021) · Figshare · doi:10.6084/m9.figshare.13545593
Additional file 14 of The R-enantiomer of ketorolac reduces ovarian cancer tumor burden in vivo
Grimes, M. M., Kenney, S. R., Dominguez, D. R., Brayer, K. J., Guo, Y., Wandinger‐Ness, A., & Hudson, L. G. (2021) · Figshare · doi:10.6084/m9.figshare.13545572
Additional file 12 of The R-enantiomer of ketorolac reduces ovarian cancer tumor burden in vivo
Grimes, M. M., Kenney, S. R., Dominguez, D. R., Brayer, K. J., Guo, Y., Wandinger‐Ness, A., & Hudson, L. G. (2021) · Figshare · doi:10.6084/m9.figshare.13545566
Metadata
- Authors
- Christie, E. L., & Bowtell, D. D. L.
- Affiliations
- The University of Melbourne (AU)
- Corresponding author
- Christie, E.L.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2017-11
- Volume
- 28
- Issue
- suppl_8
- Pages
- viii13-viii15
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2772038399
- Cited by
- 220
- References
- 14
- Citations by year
- 2026: 13 · 2025: 13 · 2024: 31 · 2023: 35 · 2022: 38 · 2021: 47 · 2020: 26 · 2019: 15 · 2018: 2
- FWCI
- 13.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Health and Medical Research Council (APP1092856)
- NHMRC (GNT1124309)
- Victorian Cancer Agency (ECSG15012)
- U.S. Army Medical Research and Materiel Command (DAMD17-01-1-0729)
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- high-grade serous ovarian cancer, recurrent ovarian cancer, biomarkers, drug resistance mechanisms
- MeSH terms
- Antineoplastic Agents, Female, Humans, Neoplasm Recurrence, Local, Ovarian Neoplasms, Cystadenocarcinoma, Serous, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
